Holen Sie sich die Stockscreener-App
19.41
1.61%
-0.32
Schlusskurs vom Vortag:
$19.73
Offen:
$19.61
24-Stunden-Volumen:
1.20M
Relative Volume:
0.48
Marktkapitalisierung:
$2.50B
Einnahmen:
$715.22M
Nettoeinkommen (Verlust:
$-250.10M
KGV:
-9.5616
EPS:
-2.03
Netto-Cashflow:
$-205.58M
1W Leistung:
-3.03%
1M Leistung:
-20.83%
6M Leistung:
+9.86%
1J Leistung:
-33.04%
1-Tages-Spanne:
$19.35
$19.83
1-Wochen-Bereich:
$19.35
$20.70
52-Wochen-Spanne:
$16.10
$35.72
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Vergleichen Sie APLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
19.40 | 2.50B | 715.22M | -250.10M | -205.58M | -2.03 |
|
ARGX
Argen X Se Adr
|
917.15 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
202.62 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.96 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ONC
Beone Medicines Ltd Adr
|
356.02 | 40.27B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
704.88 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-06 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-09-26 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-16 | Eingeleitet | William Blair | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
| 2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-02 | Eingeleitet | Mizuho | Neutral |
| 2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Bestätigt | Citigroup | Buy |
| 2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-17 | Fortgesetzt | Stifel | Buy |
| 2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-09-10 | Bestätigt | Credit Suisse | Neutral |
| 2021-09-10 | Bestätigt | Needham | Buy |
| 2021-09-10 | Bestätigt | Oppenheimer | Outperform |
| 2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-08-19 | Eingeleitet | Jefferies | Buy |
| 2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2020-11-19 | Eingeleitet | Needham | Buy |
| 2020-09-01 | Eingeleitet | Stifel | Buy |
| 2020-07-20 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
| 2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Underperform |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Will Apellis Pharmaceuticals Inc. stock deliver better than expected guidance2025 Market Overview & Low Drawdown Momentum Ideas - newser.com
Risk vs reward if holding onto Apellis Pharmaceuticals Inc.2025 Top Gainers & Stepwise Trade Signal Implementation - newser.com
Why Apellis Pharmaceuticals Inc. (1JK) stock stays on buy listsWeekly Investment Recap & Fast Exit and Entry Strategy Plans - newser.com
Published on: 2025-11-19 03:53:39 - newser.com
Can Apellis Pharmaceuticals Inc. stock resist sector downturnsMarket Weekly Review & AI Driven Price Predictions - newser.com
Can Apellis Pharmaceuticals Inc. stock beat analyst upgradesMarket Activity Report & Safe Capital Allocation Plans - newser.com
Using AI based signals to follow Apellis Pharmaceuticals Inc.Market Sentiment Report & Free Technical Confirmation Trade Alerts - newser.com
Will Apellis Pharmaceuticals Inc. see short term momentum2025 Market Overview & AI Forecast for Swing Trade Picks - newser.com
Apellis Pharma general counsel Watson sells $100k in stock By Investing.com - Investing.com Canada
Apellis Pharma general counsel Watson sells $100k in stock - Investing.com
Why Apellis Pharmaceuticals Inc. (1JK) stock could rally strongly2025 Bull vs Bear & Smart Money Movement Alerts - newser.com
Why Apellis Pharmaceuticals Inc. stock is rated strong buyJuly 2025 Opening Moves & Technical Pattern Alert System - newser.com
Apellis Pharmaceuticals (BIT:1APLS) Price Target Decreased by 10.35% to 30.35 - Nasdaq
How Apellis Pharmaceuticals Inc. stock performs in weak economy2025 Growth vs Value & Fast Exit and Entry Strategy Plans - newser.com
What high frequency data says about Apellis Pharmaceuticals Inc.2025 Earnings Impact & Weekly High Momentum Picks - newser.com
Will breakout in Apellis Pharmaceuticals Inc. lead to full recovery2025 Short Interest & Real-Time Volume Triggers - newser.com
(APLS) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
How to build a dashboard for Apellis Pharmaceuticals Inc. stockVolume Spike & Free Daily Entry Point Trade Alerts - newser.com
Does Apellis Pharmaceuticals Inc. (1JK) stock trade below intrinsic valueJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - newser.com
Will Apellis Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 Volume & Fast Gaining Stock Reports - newser.com
Apellis Pharmaceuticals Inc. stock prediction for this weekJuly 2025 Technicals & Expert Curated Trade Setup Alerts - newser.com
How interest rate cuts could boost Apellis Pharmaceuticals Inc. stockJuly 2025 Outlook & Stepwise Entry/Exit Trade Alerts - newser.com
Published on: 2025-11-14 10:40:48 - newser.com
Published on: 2025-11-13 18:42:44 - newser.com
Regression analysis insights on Apellis Pharmaceuticals Inc. performanceTreasury Yields & AI Forecasted Stock Moves - newser.com
Can Apellis Pharmaceuticals Inc. stock sustain market leadershipQuarterly Growth Report & High Accuracy Buy Signal Tips - newser.com
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years - BioSpace
Is Five-Year SYFOVRE Data Shifting the Investment Case for Apellis Pharmaceuticals (APLS)? - Yahoo Finance
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.13%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):